Mitochondrial bound type II hexokinase: A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention

Peter L Pedersen, Saroj Mathupala, Annette Rempel, J. F. Geschwind, Young Hee Ko

Research output: Contribution to journalArticle

Abstract

Despite more than 75 years of research by some of the greatest scientists in the world to conquer cancer, the clear winner is still cancer. This is reflected particularly by liver cancer that worldwide ranks fourth in terms of mortality with survival rates of no more than 3-5%. Significantly, one of the earliest discovered hallmarks of cancer had its roots in Bioenergetics as many tumors were found in the 1920s to exhibit a high glycolytic phenotype. Although research directed at unraveling the underlying basis and significance of this phenotype comprised the focus of cancer research for almost 50 years, these efforts declined greatly from 1970 to 1990 as research into the molecular and cell biology of this disease gained center stage. Certainly, this change was necessary as the new knowledge obtained about oncogenes, gene regulation, and programmed cell death once again placed Bioenergetics in the limelight of cancer research. Thus, we now have a much better molecular understanding of the high glycolytic phenotype of many cancers, the pivotal roles that Type II hexokinase-mitochondrial interactions play in this process to promote tumor cell growth and survival, and how this new knowledge can lead to improved therapies that may ultimately turn the tide on our losing war on cancer.

Original languageEnglish (US)
Pages (from-to)14-20
Number of pages7
JournalBiochimica et Biophysica Acta - Bioenergetics
Volume1555
Issue number1-3
DOIs
StatePublished - Sep 10 2002

Fingerprint

Hexokinase
Growth
Neoplasms
Tumors
Cytology
Research
Therapeutics
Molecular biology
Phenotype
Tides
Cell growth
Cell death
Energy Metabolism
Gene expression
Liver
Liver Neoplasms
Oncogenes
Cell Biology
Molecular Biology
Cell Survival

Keywords

  • Cancer
  • Drug targeting
  • Gene regulation
  • Glycolysis
  • Hexokinase
  • Mitochondria

ASJC Scopus subject areas

  • Biophysics

Cite this

Mitochondrial bound type II hexokinase : A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. / Pedersen, Peter L; Mathupala, Saroj; Rempel, Annette; Geschwind, J. F.; Ko, Young Hee.

In: Biochimica et Biophysica Acta - Bioenergetics, Vol. 1555, No. 1-3, 10.09.2002, p. 14-20.

Research output: Contribution to journalArticle

Pedersen, Peter L ; Mathupala, Saroj ; Rempel, Annette ; Geschwind, J. F. ; Ko, Young Hee. / Mitochondrial bound type II hexokinase : A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. In: Biochimica et Biophysica Acta - Bioenergetics. 2002 ; Vol. 1555, No. 1-3. pp. 14-20.
@article{02d2298c3a2a4caa9d8406675504d1d4,
title = "Mitochondrial bound type II hexokinase: A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention",
abstract = "Despite more than 75 years of research by some of the greatest scientists in the world to conquer cancer, the clear winner is still cancer. This is reflected particularly by liver cancer that worldwide ranks fourth in terms of mortality with survival rates of no more than 3-5{\%}. Significantly, one of the earliest discovered hallmarks of cancer had its roots in Bioenergetics as many tumors were found in the 1920s to exhibit a high glycolytic phenotype. Although research directed at unraveling the underlying basis and significance of this phenotype comprised the focus of cancer research for almost 50 years, these efforts declined greatly from 1970 to 1990 as research into the molecular and cell biology of this disease gained center stage. Certainly, this change was necessary as the new knowledge obtained about oncogenes, gene regulation, and programmed cell death once again placed Bioenergetics in the limelight of cancer research. Thus, we now have a much better molecular understanding of the high glycolytic phenotype of many cancers, the pivotal roles that Type II hexokinase-mitochondrial interactions play in this process to promote tumor cell growth and survival, and how this new knowledge can lead to improved therapies that may ultimately turn the tide on our losing war on cancer.",
keywords = "Cancer, Drug targeting, Gene regulation, Glycolysis, Hexokinase, Mitochondria",
author = "Pedersen, {Peter L} and Saroj Mathupala and Annette Rempel and Geschwind, {J. F.} and Ko, {Young Hee}",
year = "2002",
month = "9",
day = "10",
doi = "10.1016/S0005-2728(02)00248-7",
language = "English (US)",
volume = "1555",
pages = "14--20",
journal = "Biochimica et Biophysica Acta - Bioenergetics",
issn = "0005-2728",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Mitochondrial bound type II hexokinase

T2 - A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention

AU - Pedersen, Peter L

AU - Mathupala, Saroj

AU - Rempel, Annette

AU - Geschwind, J. F.

AU - Ko, Young Hee

PY - 2002/9/10

Y1 - 2002/9/10

N2 - Despite more than 75 years of research by some of the greatest scientists in the world to conquer cancer, the clear winner is still cancer. This is reflected particularly by liver cancer that worldwide ranks fourth in terms of mortality with survival rates of no more than 3-5%. Significantly, one of the earliest discovered hallmarks of cancer had its roots in Bioenergetics as many tumors were found in the 1920s to exhibit a high glycolytic phenotype. Although research directed at unraveling the underlying basis and significance of this phenotype comprised the focus of cancer research for almost 50 years, these efforts declined greatly from 1970 to 1990 as research into the molecular and cell biology of this disease gained center stage. Certainly, this change was necessary as the new knowledge obtained about oncogenes, gene regulation, and programmed cell death once again placed Bioenergetics in the limelight of cancer research. Thus, we now have a much better molecular understanding of the high glycolytic phenotype of many cancers, the pivotal roles that Type II hexokinase-mitochondrial interactions play in this process to promote tumor cell growth and survival, and how this new knowledge can lead to improved therapies that may ultimately turn the tide on our losing war on cancer.

AB - Despite more than 75 years of research by some of the greatest scientists in the world to conquer cancer, the clear winner is still cancer. This is reflected particularly by liver cancer that worldwide ranks fourth in terms of mortality with survival rates of no more than 3-5%. Significantly, one of the earliest discovered hallmarks of cancer had its roots in Bioenergetics as many tumors were found in the 1920s to exhibit a high glycolytic phenotype. Although research directed at unraveling the underlying basis and significance of this phenotype comprised the focus of cancer research for almost 50 years, these efforts declined greatly from 1970 to 1990 as research into the molecular and cell biology of this disease gained center stage. Certainly, this change was necessary as the new knowledge obtained about oncogenes, gene regulation, and programmed cell death once again placed Bioenergetics in the limelight of cancer research. Thus, we now have a much better molecular understanding of the high glycolytic phenotype of many cancers, the pivotal roles that Type II hexokinase-mitochondrial interactions play in this process to promote tumor cell growth and survival, and how this new knowledge can lead to improved therapies that may ultimately turn the tide on our losing war on cancer.

KW - Cancer

KW - Drug targeting

KW - Gene regulation

KW - Glycolysis

KW - Hexokinase

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=0037056002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037056002&partnerID=8YFLogxK

U2 - 10.1016/S0005-2728(02)00248-7

DO - 10.1016/S0005-2728(02)00248-7

M3 - Article

C2 - 12206885

AN - SCOPUS:0037056002

VL - 1555

SP - 14

EP - 20

JO - Biochimica et Biophysica Acta - Bioenergetics

JF - Biochimica et Biophysica Acta - Bioenergetics

SN - 0005-2728

IS - 1-3

ER -